Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP7 | P09237 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL609845 | 0.83 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3PDE4B | |
| SCHEMBL19686595 | 0.83 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3PDE4B | |
| SCHEMBL21063456 | 0.81 | KDM1A (0.33) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL21098062 | 0.81 | NR1H2 (0.43) | PDE4B | |
| SCHEMBL21063482 | 0.81 | NR1H2 (0.43) | PDE4B | |
| SCHEMBL609419 | 0.81 | NR1H2 (0.43) | PDE4B | |
| SCHEMBL19686575 | 0.79 | CHRNB2 (0.40) | CHRNB2CHRNA4CHRNB4CHRNA3PDE4B | |
| SCHEMBL14290751 | 0.75 | CHRNB2 (0.48) | CHRNB2CHRNA4CHRNB4CHRNA3PDE4B | |
| SCHEMBL608827 | 0.72 | PDE4B (0.40) | PDE4BHSD11B1MMP1MMP3MMP7 | |
| SCHEMBL12206742 | 0.71 | HDAC2 (0.36) | CHRNB2CHRNA4CHRNB4CHRNA3PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040953-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20120040953-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20120040953-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| WO-2010103335-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040953-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, GPR132, FFAR2 | CHRNB2 1174/4885CHRNA4 1589/4885CHRNB4 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.